A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.

Also called NCT01473420

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 320 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01473420
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01473420. Randomized; quadruple masking; primary purpose treatment. Start 2012-01-17 (actual); primary completion 2014-02-28 (actual). Results posted on 2018-06-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Acronym
AiME - 13
Condition
Chronic Renal Failure
Intervention (Biological)
Epoetin Hospira
Intervention (Biological)
Epogen Amgen
Lead sponsor
Pfizer (class: industry)
Collaborator
Hospira, now a wholly owned subsidiary of Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01473420
Content hash
9d128ad0f9d000d9936ee04f61706b134e561eadcec77d0a2b28cdd1aa7a20b9